- Home
- AMRN vs CAPR Comparison
AMRN vs CAPR Comparison
Compare AMRN & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- CAPR
- Stock Information
- Founded
- AMRN 1989
- CAPR 2005
- Country
- AMRN Ireland
- CAPR United States
- Employees
- AMRN N/A
- CAPR N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMRN Health Care
- CAPR Health Care
- Exchange
- AMRN Nasdaq
- CAPR Nasdaq
- Market Cap
- AMRN 339.8M
- CAPR 324.6M
- IPO Year
- AMRN 1993
- CAPR N/A
- Fundamental
- Price
- AMRN $15.93
- CAPR $4.66
- Analyst Decision
- AMRN Strong Sell
- CAPR Strong Buy
- Analyst Count
- AMRN 1
- CAPR 6
- Target Price
- AMRN $12.00
- CAPR $23.17
- AVG Volume (30 Days)
- AMRN 109.8K
- CAPR 1.9M
- Earning Date
- AMRN 10-29-2025
- CAPR 11-10-2025
- Dividend Yield
- AMRN N/A
- CAPR N/A
- EPS Growth
- AMRN N/A
- CAPR N/A
- EPS
- AMRN N/A
- CAPR N/A
- Revenue
- AMRN $226,733,000.00
- CAPR $11,130,509.00
- Revenue This Year
- AMRN N/A
- CAPR N/A
- Revenue Next Year
- AMRN N/A
- CAPR $7,894.07
- P/E Ratio
- AMRN N/A
- CAPR N/A
- Revenue Growth
- AMRN N/A
- CAPR N/A
- 52 Week Low
- AMRN $7.08
- CAPR $4.40
- 52 Week High
- AMRN $20.90
- CAPR $20.75
- Technical
- Relative Strength Index (RSI)
- AMRN 41.03
- CAPR 31.84
- Support Level
- AMRN $15.74
- CAPR $5.52
- Resistance Level
- AMRN $17.25
- CAPR $6.01
- Average True Range (ATR)
- AMRN 0.71
- CAPR 0.49
- MACD
- AMRN 0.04
- CAPR -0.06
- Stochastic Oscillator
- AMRN 40.64
- CAPR 12.42
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.